Valeant says wait one more year for turnaround; shares fall
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Valeant Pharma (VRX) Setting Stage for Potential Capital Raise in 2018 - Evercore ISI's Raffat
February 28, 2018 9:50 AM ESTEvercore ISI analyst Umer Raffatt thinks Valeant Pharma (NYSE: VRX) could tap the capital market this year.
He notes while Valeant gave no clear answer on whether Valeant will look to raise capital near term and emphasized that there... More
